CERN Supported Research Uses New Approach to Calculate Drug Doses for Ependymoma Treatment
St. Jude Children’s Research Hospital scientists have used sophisticated pharmacologic modeling and simulation to translate preclinical findings into a phase I clinical trial of a chemotherapy, 5-FU, for ependymoma treatment. The research marked the first time the approach has been used to calculate drug doses for a clinical trial in pediatric brain tumor patients. Supported by the CERN Foundation.
"The approach used in this study should serve as a template for drug development, especially for rare diseases like ependymoma where the need for promising therapies is high but few patients are available for clinical trials," said corresponding author Clinton Stewart, Pharm.D., a member of the St. Jude Department of Pharmaceutical Sciences.